XML 119 R15.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Discontinued Operations (Notes)
 12 Months Ended
Dec. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued Operations DISCONTINUED OPERATIONS
In the fourth quarter of 2018, the Company's Board of Directors authorized it to pursue a plan to sell the REG Life Sciences core assets and business. The Company recorded an impairment loss, net of tax, of $11,226 on classifying the REG Life Sciences assets as held for sale reflecting the fair value of the estimated proceeds from the sale, net of costs to sell. This valuation technique is considered as Level 3 pricing category.
In May 2019, the sale of REG Life Sciences core assets and business was closed. The Company recorded a loss, net of tax, on sale of assets of $1,250. There is no income tax impact from discontinued operations for all periods due to the impact of valuation allowance.
Loss on Discontinued Operations:
Discontinued Operations
 
For the years ended December 31,
 
2019
 
2018
 
2017
Other revenues
$
1,786

 
$
5,856

 
$
3,588

Other costs of goods sold
(2,200
)
 
(4,697
)
 
(4,360
)
Research and development expense
(8,056
)
 
(15,152
)
 
(11,673
)
Other income (expense), net
53

 
13,907

 
(355
)
Loss on sale of assets
(1,250
)
 
—

 
—

Pre-tax loss from discontinued operations
(9,667
)
 
(86
)
 
(12,800
)
Pre-tax impairment loss on assets classified as held for sale
—

 
(11,226
)
 
—

Income tax expense
—

 
—

 
—

Loss on discontinued operations
$
(9,667
)
 
$
(11,312
)
 
$
(12,800
)

Reconciliation of the Carrying Amounts of Major Classes of Assets and Liabilities Included in Assets and Liabilities Held for Sale:
 
2019
 
2018
Machinery and equipment, net
$
—

 
$
824

In-process research and development
—

 
13,652

Impairment loss recognized on assets classified as held for sale
—

 
(11,226
)
Total assets classified as held for sale
$
—

 
$
3,250